ARTICLE | Company News
Veracyte, Loxo team up for TRK, RET targeted therapies
April 13, 2018 4:52 PM UTC
Molecular diagnostics company Veracyte Inc. (NASDAQ:VCYT) said Loxo Oncology Inc. (NASDAQ:LOXO) will use Veracyte's Afirma Xpression Atlas platform to develop targeted therapies for thyroid cancers with tropomyosin receptor kinase (TRK) fusions and Ret proto-oncogene (RET) alterations. Financial and deal terms were not disclosed.
The RNA sequencing-based Afirma Xpression Atlas is an extension of Veracyte's Afirma Genomic Sequencing Classifier (GSC)...